AEOLUS PHARMACEUTICALS, INC. 4

4 · AEOLUS PHARMACEUTICALS, INC. · Filed Jul 14, 2006

Form 4

Period: 2005-12-30

Chief Executive Officer

Transactions

Exercise/Conversion
Common Stock
2005-12-30$1.00/sh+20,833$20,833→ 102,582 total
Exercise/Conversion
Common Stock
2006-03-31$1.00/sh+19,760$19,760→ 122,342 total
Exercise/Conversion
Non-Qualified Stock Option
2006-03-31+1,073→ 145,835 total
Exercise: $1.00From: 2005-07-12Exp: 2015-07-12→ Common Stock (1,073 underlying)
Exercise/Conversion
Non-Qualified Stock Option
2006-07-10+20,833→ 125,002 total
Exercise: $1.00From: 2005-07-12Exp: 2015-07-12→ Common Stock (20,833 underlying)
Exercise/Conversion
Incentive Stock Option
2006-03-31+19,760→ 0 total
Exercise: $1.00From: 2005-07-12Exp: 2015-07-12→ Common Stock (19,760 underlying)
Exercise/Conversion
Common Stock
2006-07-10$1.00/sh+20,833$20,833→ 144,248 total
Exercise/Conversion
Common Stock
2006-03-31$1.00/sh+1,073$1,073→ 123,415 total
Exercise/Conversion
Incentive Stock Option
2005-12-30+20,833→ 19,760 total
Exercise: $1.00From: 2005-07-12Exp: 2015-07-12→ Common Stock (20,833 underlying)

Footnotes (1)

[F1]Shares are held in trust by Aeolus Pharmaceuticals, Inc. and not subject to sale by Mr. Burgoon until such time as Mr. Burgoon's position with Aeolus Pharmaceuticals, Inc. has ended, or unless otherwise agreed to by the Board of Directors.

Documents

1 file